Karyopharm implements 2026 Leadership Cash Retention Program with $3.715M in total awards to four executives

Karyopharm Therapeutics Inc.

CEO Richard Paulson receives $1.725M; CFO Lori Macomber $625K; CMO Reshma Rangwala $725K; CDO Stuart Poulton $640K.
Program replaces 2026 Annual Bonus Plan guaranteed amounts; awards are lump sum cash.
Awards subject to repayment if executive leaves before 12 months or 30 days post-corporate event, unless termination is without cause, good reason, death/disability.
Retention program aims to incentivize key employees during period of expected catalysts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.